Still, patients with specific conditions may require caution
Legitimate Research Directions: Some peptides DO have potential and are being properly studied: Thymosin Alpha-1: Immune support (approved in 35+ countries, trials in US) BPC-157: IF proper human trials ever happen LL-37: Antimicrobial applications Others: Many peptides have theoretical promise But ONLY if studied properly: Randomized controlled trials Safety studies FDA approval process Medical supervision The Problem: Most "wellness peptides" will NEVER go through this process because: They can't be patented (no profit incentive) Companies would rather sell in gray market Proper trials cost $100M+ If trials show they DON'T work, the market disappears So we're stuck in limbo: promising animal data, zero human data, aggressive marketing
Results: For endogenous antioxidants, a bidirectional two-sample MR analysis was conducted
This is a critical reminder of the perpetual need for supply chain integrity in the pharmaceutical industry
The researchers suggest it may be a GLP-1 effect, since curcumin stimulates GLP-1 in rodents, as well as in cells in a petri dish, but there hasnt been a human studyuntil now
Kolkata, India (WBCIL), focusing on preformulation studies, force degradation assessments, and analytical techniques including UV, IR spectroscopy, and HPLC